Welcome to the Week in Review.
Growing Momentum Around International Reference Pricing
Senators Josh Hawley (R-MO) and Peter Welch (D-VT) unveiled a bipartisan bill that would bar drug companies from charging Americans more than the international average price for a specific prescription drug, adding to growing momentum around international reference pricing. Meanwhile, the Trump administration is considering a separate proposal that would tie Medicaid drug payments to foreign prices as part of broader budget reconciliation legislation, with new reports that Trump is expected to sign an executive order pursuing the initiative as soon as Monday. P4AD supports the principle that Americans shouldn’t be paying up to eight times more than patients in other countries, and we’re encouraged to see bipartisan efforts to lower drug prices through mechanisms such as international reference pricing. These proposals have the potential to deliver real relief for patients, but ultimately, the devil will be in the details. We’ll be watching closely to ensure any final plan truly lowers prices without restricting access here or abroad. — [POLITICO, Stat News, Axios, Endpoints News, Bloomberg, POLITICO]
P4AD Holds Community Town Hall
On Tuesday, we hosted a live Town Hall to answer questions from our community and shared the latest in our fight to stop pharma, its lobbyists, and allies from rolling back the progress we’ve made to lower drug prices. We covered everything from the threats to Medicare negotiation, to the potential harm of tariffs, to recent competition bills progressing through Congress, to efforts to reform the PBM system. Thank you to our community members who joined us live and to those of you who wrote to us with close to 600 questions! If you missed it, check out the video here!
Drug Spending Hits Record High As Patients Struggle to Afford Medications
According to Axios’ coverage of a new IQVIA report, Americans’ out-of-pocket spending on prescription drugs has surged 25% over the last five years, reaching a historic high of $98 billion last year. Even though total net medicine spending rose 11.4% last year, hitting a massive $487 billion, more than one-quarter of new prescriptions went unfilled — largely because they aren’t covered by insurance. It’s no surprise that nearly 90% of voters, including 89% of Trump voters, say prescription drug prices are too high, with nearly 60% of Americans reporting struggling to afford their medications in the last 12 months. Americans – who pay between four and eight times more than people in other wealthy countries – are urgently demanding that the White House and Congress do more to address this crisis of high drug prices. — [Axios, Arnold Ventures]
ICYMI
In a powerful report for ProPublica, David Armstrong reflects on the cancer drug Revlimid — the same drug that helped treat his own multiple myeloma — and the industry tactics that kept its price high for years. The piece, which includes reflections from P4AD’s David Mitchell, who is also a multiple myeloma patient, captures both the human stakes and the corporate strategies that put profit above patients.
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
P4AD and AARP Push Back Against Pharma’s EPIC Act
In an exclusive first reported by The Hill, P4ADNow and AARP sent a joint letter to top House committee leaders urging them to reject the EPIC Act (H.R. 1492) — a pharmaceutical industry-backed bill that would delay Medicare drug price negotiation for small-molecule drugs from 9 to 13 years. The move comes as lawmakers consider what to include in the upcoming reconciliation package, where the drug industry is pushing for the bill’s inclusion. The letter argues that if Congress wants to “align” timelines for biologics and pills, as President Trump recently suggested, it should do so at 9 years, not 13, to protect savings for patients and taxpayers. Blocking earlier negotiation would mean drugs like Eliquis and Jardiance, which were negotiated in the first round, would not be eligible, costing Americans billions in higher prices. – [P4ADNow, The Hill, Axios, AARP]
Pharma-Backed Patent Bills Return
Yesterday, Senators Thom Tillis and Chris Coons reintroduced two harmful bills — the PREVAIL Act and PERA — that would entrench pharma monopolies and block lower-cost competition. P4ADNow strongly opposes both bills, which would weaken key patent oversight tools and expand patent protections that keep drug prices high. Patients helped defeat these harmful proposals in the last Congress, and are ready to do it again. With 78% of voters saying drug companies are focused on profits over people, advancing these bills isn’t just bad policy — it’s bad politics. – [P4ADNow, Arnold Ventures]
Pharma Opposes Tariffs — They Prefer to Hike Prices Themselves
The Trump administration’s investigation into pharmaceutical imports has raised the possibility of a 25% tariff on drugs and ingredients. A new PhRMA-commissioned report warns tariffs could raise U.S. drug prices by nearly 13% and cost Americans $51 billion annually — but let’s be clear: drug companies set drug prices, and while we agree tariffs would drive up costs and threaten access, Big Pharma’s warning is more about protecting its bottom line than protecting patients. As P4AD’s Merith Basey told The Lancet Oncology, it’s patients who would suffer the most, facing higher prices, potential shortages, and threats to the progress made under Medicare drug price negotiation. – [Reuters, Consumer Affairs, Pharmaphorum, The Lancet Oncology]
Pharma’s Scapegoat: Inside the $31M Campaign to Shift Blame
A new Wall Street Journal article reveals how Big Pharma’s $31 million lobbying blitz last year, plus another $13 million in Q1 2025, helped shift blame for high drug prices onto pharmacy benefit managers (PBMs). From funding minority-led nonprofits to underwriting conservative media campaigns, the piece exposes how drug companies are shaping the narrative to deflect scrutiny. It’s a calculated strategy that makes strange bedfellows — and while P4AD supports genuine reforms to rein in PBMs, it’s clear the drug industry is more focused on shifting blame and protecting profits than fixing the system. – [The Wall Street Journal]
ICYMI
P4AD released an open letter to our community – on the 100th day of President Trump’s second term – reaffirming our commitment to lowering drug prices. While Pharma ramps up lobbying and pushes carveouts like the EPIC Act, patients are organizing, fighting back, and driving progress. The fight continues.
Subscribe to the WEEK IN REVIEW here.
PREVAIL and PERA Bills Would Undermine Reforms, Extend Monopolies, and Keep Drug Prices High
WASHINGTON, D.C. — Patients For Affordable Drugs Now strongly opposes the reintroduction of two harmful patent bills — the PREVAIL Act and the Patent Eligibility Restoration Act — which would further enable abuse of the patent system and prolong monopolies on brand-name medications.
“These dangerous bills would further rig the patent system in favor of the pharmaceutical industry,” said Merith Basey, Executive Director of Patients For Affordable Drugs Now. “At a time when one in three Americans can’t afford their prescriptions, Congress should be working day and night to lower prices, but instead, Senators Tillis and Coons are siding with Big Pharma and helping the industry further entrench its power at the expense of patients”.
While nearly 90% of Americans say prescription drug prices are too high — and more than 9 in 10 voters across party lines believe Congress must act to lower them — these proposals move in the wrong direction. Today, 29 million Americans are considered “cost desperate,” struggling to afford the medications and care they need. Yet instead of reining in Big Pharma, Congress is poised to expand its power — even as nearly two-thirds of voters view pharmaceutical companies unfavorably and see them as one of the top drivers of high health care costs. A full 78% of voters believe drug companies are focused on profits, not patients. Advancing these bills would not only undermine popular reforms but also stifle competition and hand even more control to an industry voters know is rigging the system against them.
BACKGROUND
P4ADNow supports the following patent reform bills;
###
Patients For Affordable Drugs Now, is the only national, patient advocacy organization focused exclusively on policies to lower drug prices. We empower and mobilize patients and allies, hold accountable those in power, and fight to shape and achieve system-changing policies that make prescription drugs affordable for all people in the United States. P4ADNow is bipartisan and does not accept funding from organizations that profit from the development or distribution of prescription drugs. To learn more visit; PatientsForAffordableDrugsNOW.org.
Welcome to the Week in Review.
NEW POLL: GOP Voters Overwhelmingly Back Medicare Negotiation
A major new poll from Republican polling firm Fabrizio Ward confirms what patients have long known: Voters overwhelmingly support bold action to lower drug prices, and their views are driven by their lived experiences. The survey shows 89% of American voters, including 89% of Trump voters, say prescription drug prices are too high. Nearly 60% have struggled to afford their medications, and a staggering 86% of all voters support Medicare negotiating prices for all prescription drugs by capping prices no higher than what other wealthy nations pay. Support for negotiation jumps to 72% among Republicans, while favorability for pharma is underwater among Trump voters at -43. With Republicans gaining 20 points on the generic ballot when they back Medicare negotiation, the takeaway is clear: Defending Medicare negotiation is not just good policy – it’s good politics. — [Arnold Ventures]
Pharma’s Record-Breaking Lobbying Spend
Big Pharma is spending more than ever to block reforms and protect its monopoly pricing power. PhRMA, the industry’s top lobbying group, reported a record $12.9 million in federal lobbying expenditures in Q1 of 2025 – the most it’s ever spent in a single quarter – to roll back provisions of the 2022 prescription drug law, secure carveouts like the EPIC Act, and keep prices high for patients. The surge in spending also reflects mounting pressure over Trump’s tariff threats, with companies like Pfizer and Eli Lilly sharply increasing their own lobbying budgets and hiring Trump-linked lobbyists to shape policy behind closed doors. Lilly nearly doubled its Q1 spending compared to last year, hitting $3.4 million, while Pfizer jumped to $4.2 million. As one in three Americans struggles to afford their prescriptions, the industry’s multimillion-dollar blitz to preserve its power speaks volumes. — [Endpoints, Sludge, POLITICO, POLITICO]
‘Most Favored Nation’ Pricing Floated For 2nd Time
The Trump administration is reportedly considering a “Most Favored Nation” (MFN) policy that would tie Medicare drug prices to those paid in other wealthy countries, where prices are often dramatically lower. Originally introduced during President Trump’s first term and blocked in court, the MFN proposal would prevent Medicare from paying more than the lowest price charged for a drug in peer nations, adjusted for economic factors. While the concept has some support, it remains deeply unpopular with pharmaceutical companies. Trump’s team is said to be weighing options for reviving the policy through a new Medicare demonstration model or legislation. No formal proposal has been released yet, but recent comments and documents suggest the idea is gaining traction once again. — [STAT News, Reuters, BioSpace, RAND]
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
Trump’s Executive Order Includes Massive Pharma Giveaway
President Trump’s new executive order (EO) on drug pricing proposes a sweeping change to the Medicare negotiation program that would delay negotiations for small-molecule drugs, typically lower-cost pills, by four years. This delay, which is a major win for drug companies, is outlined in the EPIC Act. If implemented, the policy would shield billions in pharma profits and gut the core of the 2022 prescription drug law’s widely popular cost-saving reforms. According to KFF, more than half of the drugs selected in the first two rounds of negotiation would have been ineligible under this proposal. The policy would have exempted from negotiation some of the most widely used and most expensive drugs covered by Medicare, like Eliquis, Jardiance, and Ozempic, for years longer than under current law, helping pharma to maintain their monopolies for longer at the expense of patients. The industry argues that small-molecule drugs are unfairly subject to negotiation sooner than biologics. But if the Trump Administration truly wants parity, as stated in the EO, it should align both at nine years – not extend monopoly pricing even further. Nine years is already a generous runway before Medicare can negotiate lower prices. The administration is clearly signaling that it sees high drug prices as an urgent issue – but if it’s serious about lowering costs, cutting off one of the most powerful tools in the toolbox is counterintuitive. With fewer high-priced drugs eligible for negotiation, achieving the administration’s stated goal of greater savings for Medicare and patients becomes significantly harder. — (New York Times, Fierce Pharma, The Hill, Healthcare Finance, MedCity News, KFF, Health Affairs, P4ADNow, BioCentury.
Yes, We’re Still Talking About Tariffs
The Trump administration has formally launched a national security investigation into imported pharmaceuticals and drug ingredients – a move that experts warn will raise prices and disrupt supply chains. While Big Pharma could absorb the costs, history shows they’ll pass them on to patients instead. Generics like heparin, which is used daily in hospitals, are especially vulnerable to tariffs due to reliance on raw materials from countries like China. As The Washington Post reports, patients like 66-year-old Wanda, who relies on daily infusions of heparin to survive, could face life-threatening disruptions if tariffs trigger major price hikes or shortages. Health economists warn that the U.S. system isn’t currently equipped to urgently replace global supply chains, and hospitals may be forced to make dangerous tradeoffs. Even as drug companies rush to announce increases in U.S. investment, this policy shift will hit patients long before any promised benefits materialize. As Trump doubles down and drugmakers continue to prioritize profits above all else, it’s patients who will end up paying the price. — (STAT News, POLITICO, Bloomberg, Washington Post, POLITICO, New York Times)
States Push Back on PBM Power Amid National Reform Debate
Momentum is building against the outsized influence of pharmacy benefit managers (PBMs), as 39 state attorneys general called on Congress to ban PBMs from owning pharmacies – a move they say would curb conflicts of interest and reduce drug costs. The plea follows Arkansas enacting the nation’s first law requiring PBMs to choose between operating as middlemen or owning pharmacies, a major step toward dismantling vertically integrated monopolies. Meanwhile, state audits, lawsuits, and a growing patchwork of legislation across the country highlight the urgent need for federal action to rein in PBM abuses and restore fair competition. – (STAT News, U.S. News & World Report, STAT News)
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
Pharma Tariffs Would Raise Drug Prices, Deepen Patient Struggles
Despite President Trump’s decision to pause broad-based tariffs on most countries, concerns are mounting as he continues to double down on potential pharmaceutical tariffs — a move that would drive up drug prices for Americans. The U.S. already pays the highest prescription drug prices in the world, and patients are worried. “Tariffs will exacerbate that problem,” Merith Basey, executive director of Patients For Affordable Drugs, told CNN. “Prescription drugs aren’t luxury goods; they’re essential to people’s health and survival.” New tariffs could increase manufacturing costs, worsen the ongoing drug shortage crisis, and make it harder for patients to access medications they need. With one in three Americans already struggling to afford their prescriptions, these added costs risk pushing more people to skip or ration their medications. P4AD will continue to monitor developments and speak out against any policy that would raise drug prices. — (POLITICO, The Hill, NBC5, CNN, POLITICO)
Courts Hear Arguments in Ongoing Lawsuits Against Medicare Negotiation
Last Friday, Boehringer Ingelheim faced a skeptical panel during oral arguments before the Second Circuit Court of Appeals, as judges questioned the company’s claims that the Medicare negotiation program imposes unconstitutional conditions. The government’s defense was so strong that the lawyer representing the case used only a fraction of their allotted time. On Tuesday, a Third Circuit panel heard challenges from Novartis and Novo Nordisk. The panel appeared unconvinced by Novartis’ argument that the program constitutes an unlawful “taking” under the Fifth Amendment. Novo Nordisk faced scrutiny over its claim that CMS unlawfully grouped six of its insulin products for negotiation. While judges appeared more engaged with Novo Nordisk’s arguments, the panel largely deferred to CMS’ authority under the law, suggesting the program remains on solid footing. These hearings mark the first time the Trump Administration has defended Medicare negotiation in court — and so far, the trend of judges remaining unconvinced by pharmaceutical corporations’ arguments is continuing. — (Bloomberg, Courthouse News, Endpoints, Inside Health Policy)
Medicare Coverage Expansion for Anti-Obesity Drugs Halted
The Trump administration has declined to finalize a Biden-era proposed rule that would have expanded Medicare coverage to include GLP-1 drugs like Ozempic and Wegovy for obesity. While the drugs remain covered for diabetes, heart disease, and sleep apnea, Medicare is still barred by law from covering them for obesity alone. The proposal’s estimated $40 billion price tag raised alarms, but the real scandal is why the drugs are priced so high to begin with. Studies show Ozempic can be manufactured for less than $5 a month, yet it carries a U.S. list price of nearly $1,000 a month – considerably higher than in comparable countries. – (Axios, CNBC, Peterson-KFF)
ICYMI: A new report from I-MAK reveals how drugmakers Novo Nordisk and Eli Lilly are abusing the patent system to extend monopolies on blockbuster GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. It’s a clear reminder why Congress must urgently pass bipartisan patent reform to restore competition, end monopoly abuse, and lower drug prices.
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
President Trump, Negotiate A “Better Deal” For Americans
P4AD launched a new national TV ad this week, airing on Fox & Friends, urging President Trump to continue defending Medicare’s ability to negotiate lower drug prices and deliver a better deal for American patients. The 30-second spot entitled “Better Deal” highlights Trump’s own statements supporting the need for Medicare to negotiate and calls on him to stand with patients, not Big Pharma lobbyists, as the second round of negotiations is underway. The ad aired amidst ongoing legal challenges from drug companies seeking to block the program, and as Trump’s DOJ has begun defending the law in court. Watch the ad below! – (Axios, YouTube)
Uncertainty Around Trump Tariffs Raises Concerns for Patients
President Trump’s newly announced tariffs have sparked growing concerns about the potential impact on drug prices and patient access. While pharmaceuticals were temporarily exempted from the latest round of tariffs, the administration has signaled that industry-specific tariffs targeting the sector are still under consideration. If implemented, these tariffs would likely increase manufacturing costs and further drive up prescription drug prices for Americans, one in three of whom are already struggling to afford their medications. We have already heard from patients anxious about rising prices and wondering if they should rush to stock up on the medications they rely on. P4AD will continue to monitor developments closely and amplify the voices of patients whose health and financial well-being hang in the balance. — (Bloomberg, Reuters, Fierce Pharma, USA Today)
Patent Bills Pass Through Committee Once Again
The Senate Judiciary Committee advanced a slate of bipartisan, pro-competition bills this week aimed at curbing patent abuses and lowering prescription drug prices. These bills – S.1040, S.1041, S.1096, S.1095, and S.1097 – would address anti-competitive tactics including product hopping, patent thicketing, pay-for-delay deals, and abuses of the FDA’s citizen petition process. The legislation would also improve coordination and communication between the FDA and the United States Patent and Trademark Office (USPTO) regarding each agency’s drug patent-related activities. The five bills have been championed by patients in our community since July 2023 and are projected to save taxpayers nearly $5 billion over the next decade. This latest vote marks an important step toward advancing reforms that promote competition and deliver long-overdue relief to patients and taxpayers. — (PatientsPushForCompetition.org)
Affordability Crisis Hits New High
A new Gallup-West Health report finds that nearly 29 million Americans are now “Cost Desperate” – unable to afford or access the care and medicine they need. The percentage of Americans struggling to pay for healthcare is at its highest level since 2021, with the burden falling hardest on Black, Latino, and low-income families. The research shows that the gap between those who can afford care and those who can’t is now wider than ever — and high drug prices are a key driver of this growing crisis. It’s yet another stark reminder that patients need relief now, and are demanding lawmakers act to rein in Big Pharma’s unchecked pricing power. – (Gallup)
ICYMI
This week, P4AD launched a new Spanish-language website to ensure Latino and Spanish-speaking communities, who are disproportionately harmed by high drug prices, are not only included in the fight for lower cost drugs they also have the tools to amplify their voices and take action.
Subscribe to the WEEK IN REVIEW here.
Welcome to the Week in Review.
As Tariffs Loom, Patients Could Pay the Price
President Trump confirmed this week that pharmaceutical tariffs remain on the table as part of a broader trade package. If imposed, tariffs of 25% or more on imported medicines and ingredients would disrupt the global supply chain, and patients would be left footing the bill. The U.S. already pays between 4-8 times what similar high-income nations pay for the same brand-name drugs. Adding tariffs would raise costs further, especially for generic medications, which account for 90% of all prescriptions in the US. New data from the Biotechnology Innovation Organization (BIO) suggests that proposed tariffs on the EU could jeopardize innovation and slow the development of new treatments for patients, as biotech companies could be left scrambling for new research and manufacturing partners. Some major drug companies have recently announced new U.S. manufacturing investments, likely in anticipation of future trade penalties. But reshoring takes years; in the meantime, patients would face higher prices and greater uncertainty. Pharma, meanwhile, could use the disruption to raise prices – exploiting chaos while continuing to fight efforts to lower costs and reform the patent system. Regardless of the policy intent, it’s patients who will bear the cost of pharmaceutical tariffs. – (Politico, Axios, Fierce Pharma, Global Trade Magazine, Desert Sun, BIO, Reuters, Forbes)
Judiciary Committee to Markup Pro-Competition Drug Pricing Bills
This Thursday, the Senate Judiciary Committee will mark up a slate of bipartisan, pro-competition bills aimed at curbing patent abuses and lowering prescription drug prices. The legislation targets tactics like patent thicketing, product hopping, and pay-for-delay deals that allow brand-name drug companies to extend monopolies and block generics and biosimilars. Previous versions of these bills – S.1040, S.1041, S.1096, S.1095, and S. 1097 – have been championed by patients in our community since July 2023. They have not only passed through Committee with bipartisan support but are projected to save taxpayers nearly $5 billion over the next decade. With one in three Americans struggling to fill their prescriptions due to cost, the Committee has a critical opportunity to advance reforms that promote competition and deliver relief to patients and taxpayers. — (Senate Judiciary Committee, PatientsPushForCompetition.org)
AFPI Outlines Drug Pricing Policies in Report
The America First Policy Institute (AFPI), a think tank founded by former Trump officials, released a new policy paper last week signaling that Trumpworld is serious about addressing the fact that Americans pay far more for prescription drugs than people in other countries. The paper revives ideas from Trump’s first term that were never implemented, and offers a more detailed roadmap than anything seen so far from the administration. While lowering prices for Americans is mentioned, the paper’s main focus is on preventing other countries from “freeloading” off U.S. investments in R&D. While we don’t share all of AFPI’s assumptions, the paper represents a notable shift and raises the prospect of potential drug pricing reforms under President Trump. (Axios, Endpoints)
ICYMI
The FTC’s lawsuit against the three largest PBMs is now in jeopardy after two commissioners were fired, raising legal questions about whether the case can proceed. We’re closely monitoring this development, which could undermine efforts to hold PBMs accountable for inflated insulin prices and restricted patient access.
Subscribe to the WEEK IN REVIEW here.